Диссертация (1174213), страница 43
Текст из файла (страница 43)
– 2017. - №33(2). – Р. 211-213.doi:10.1016/j.cjca.2016.10.007.199. Hart RG. Adjusted-dose warfarin versus aspirin for preventing stroke inpatients with atrial fibrillation /Hart RG, Pearce LA, Aguilar MI // Ann Intern Med– 2007. - №147. Р.590–592.200. Hart RG. Metaanalysis: antithrombotic therapy to prevent stroke inpatients who have nonvalvular atrial fibrillation /Hart RG, Pearce LA, Aguilar MI// Ann Intern Med. – 2007. - № 146.
Р. 857–867.201. Hart RG. Warfarin in atrial fibrillation patients with moderate chronickidney disease /Hart RG, Pearce LA, Asinger RW, Herzog CA // Clin J Am SocNephrol. – 2011. - №6. Р.2599–2604.202. Hart RG. Stroke with intermittent atrial fibrillation: incidence andpredictors during aspirin therapy. Stroke Prevention in Atrial FibrillationInvestigators /Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW,Halperin JL // J Am Coll Cardiol. – 2000.
- №35. – Р.183–187.http://dx.doi.org/10.1016/S0735-1097(99)00489-1.203. Hartmann A. Poster publication from 24 Abeitstagund furNeurologische intensive und nothallmedizin /Hartmann A. et al // Chemnitz, 2007.204. Healey JS. Prevention of atrial fibrillation with angiotensin-convertingenzyme inhibitors and angiotensin receptor blockers: a meta-analysis/Healey JS,Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ // J AmColl Cardiol.
– 2005. - №45. – Р.1832–1839.205. Heeringa J. Prevalence, incidence and lifetime risk of atrial fibrillation:the Rotterdam study /Heeringa J, van der Kuip DA, Hofman A,et al // Eur Heart J.– 2006. - № 27. –Р. 949–953.206. Heidbuchel H. Updated European Heart Rhythm Association PracticalGuide on the use of non-vitamin K antagonist anticoagulants in patients with nonvalvular atrial fibrillation /Heidbuchel H, Verhamme P, Alings M, Antz M, DienerHC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P // Europace.
– 2015. №17(10). – Р.1467-507. doi: 10.1093/europace/euv309.207. Hewson MG. Patient education through teaching for conceptual change/Hewson MG// J Gen Intern Med. – 1993. -№8. – Р.393–8.208. Hijazi Z. Cardiac biomarkers are associated with an increased risk ofstroke and death in patients with atrial fibrillation: a Randomized Evaluation ofLong-term Anticoagulation Therapy (RE-LY) substudy /Hijazi Z, Oldgren J,Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, VinereanuD, Siegbahn A, Yusuf S, Wallentin L // Circulation. – 2012.
- №125. – Р.1605–1616.209. Hijazi Z. N-terminal pro-B-type natriuretic peptide for risk assessmentin patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixabanfor the Prevention of Stroke in Subjects With Atrial Fibrillation) /Hijazi Z,Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ,255Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurrayJJ, Granger CB // J Am Coll Cardiol. – 2013. - №61. – Р.2274–2284.210.
Hohnloser SH. Rhythm or rate control in atrial fibrillationPharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial/Hohnloser SH, Kuck KH, Lilienthal J // Lancet. – 2000. - № 356. –Р. 1789–1794.211. Hohnloser SH. Incidence of stroke in paroxysmal versus sustainedatrial fibrillation in patients taking oral anticoagulation or combined antiplatelettherapy: an ACTIVE W Substudy /Hohnloser SH, Pajitnev D, Pogue J, Healey JS,Pfeffer MA, Yusuf S, et al; ACTIVE W Investigators // J Am Coll Cardiol.
– 2007.- №50. – Р.2156–2161. DOI:10.1016/j.jacc.2007.07.076212. Holmes DR Jr. Prospective randomized evaluation of the WatchmanLeft Atrial Appendage Closure device in patients with atrial fibrillation versuslong-term warfarin therapy: the PREVAIL trial /Holmes DR Jr, Kar S, Price MJ,Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY // J Am Coll Cardiol. –2014. - №64. - Р.1–12.213. Hsu JC.
International Collaborative Partnership for the Study of AtrialFibrillation (INTERAF): Rationale, Design, and Initial Descriptives /Hsu JC,Akao M, Abe M, Anderson KL, Avezum A, Glusenkamp N, Kohsaka S, Lane DA,Lip GY, Ma CS, Masoudi FA, Potpara TS, Siong TW, Turakhia MP, Tse HF,Rumsfeld JS, Maddox TM // J Am Heart Assoc. – 2016. - № 5(11).
pii: e004037.214. Hsu JC. Differences in anticoagulant therapy prescription in patientswith paroxysmal versus persistent atrial fibrillation /Hsu JC, Chan PS, Tang F,Maddox TM, Marcus GM // Am J Med. – 2015. - №128(6). Р.654.e1-654.e10. doi:10.1016/j.amjmed.2014.11.035.215. http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/#216. Hughes M. Stroke and thromboembolism in atrial fibrillation: asystematic review of stroke risk factors, risk stratification schema and costeffectiveness data /Hughes M, Lip GY // Thromb Haemost. – 2008.
- № 99. – Р.295–304.217. Huisman MV. Antithrombotic Treatment Patterns in Patients withNewly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry,Phase II /Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, DubnerSJ, Halperin JL, Ma C, Zint K, Elsaesser A, Bartels DB, Lip GY; GLORIA-AFInvestigators // Am J Med. – 2015.
- №128(12). – Р. 1306-13.e1. doi:10.1016/j.amjmed.2015.07.013.218. Huisman MV. The Changing Landscape for Stroke Prevention in AF:Findings From the GLORIA-AF Registry Phase 2 /Huisman MV, Rothman KJ,Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K,Elsaesser A, Bartels DB, Lip GY; GLORIA-AF Investigators // J Am Coll Cardiol.– 2017. - №69(7). – Р. 777-785. doi:10.1016/j.jacc.2016.11.061.219. Huxley RR. Physical activity, obesity, weight change, and risk of atrialfibrillation: the Atherosclerosis Risk in Communities study /Huxley RR, Misialek256JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A // Circ ArrhythmElectrophysiol. – 2014. - №7.
– Р.620–625.220. Hylek EM. Effect of intensity of oral anticoagulation on stroke severityand mortality in atrial fibrillation /Hylek EM, Go AS, Chang Y, et al.// N Engl JMed. – 2003. - №349. – Р. 1019–1026.221. Hypertension: clinical management of primary hypertension in adults /Clinical guidelines // CG127 - Issued: August 2011).
NICE.222. Iguchi Y. Relation of atrial fibrillation to glomerular filtration rate/Iguchi Y, Kimura K, Kobayashi K et al. // Am. J. Cardiol. - 2008. - Vol. 102 (8). P. 1056–1059.223. Inoue H. Thromboembolic events in paroxysmal vs. permanent nonvalvular atrial fibrillation. Subanalysis of the J-RHYTHM Registry /Inoue H,Atarashi H, Okumura K, Yamashita T, Kumagai N, Origasa H. // Circ J. – 2014. №78. – Р.2388–2393.
http://doi.org/10.1253/circj.CJ-14-0507.224. Jahangir A. Long-term progression and outcomes with aging in patientswith lone atrial fibrillation: a 30-year follow-up study /Jahangir A, Lee V,Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL, Hammill SC, ShenWK, Gersh BJ // Circulation. – 2007. - №115. – Р.3050–3056.225.
Jamerson K. Benazepril plus amlodipine or hydrochlorothiazide forhypertension in high-risk patients /Jamerson K, Weber MA, Bakris GL et al.ACCOMPLISH Trial Investigators // NEJM. – 2008. - № 359. – Р. 2417–28.226. Jennifer A. Blood pressure in intracerebral hemorrhage – How LowShold We Go? /Jennifer A, Frontera MD // NEJM/ - 2013/ - №368/ - Р. 24262427.227.
Jespersen SF. Use of oral anticoagulation therapy in atrial fibrillationafter stroke: results from a nationwide registry /Jespersen SF, Christensen LM,Christensen A, Christensen H // Thrombosis. – 2013. - №2013. – Р.601450228. Jibrini MB. Prevention of atrial fibrillation by way of abrogation of therenin-angiotensin system: a systematic review and meta-analysis /Jibrini MB,Molnar J, Arora RR // Am J Ther.
– 2008. - №15. – Р.36–43.229. Jun M. Warfarin Initiation, Atrial Fibrillation, and KidneyFunction: Comparative Effectiveness and Safety of Warfarin in Older Adults WithNewly Diagnosed Atrial Fibrillation /Jun M, James MT, Ma Z, Zhang J, TonelliM, McAlister FA, Manns BJ, Ravani P, Quinn RR, Wiebe N, Perkovic V, WiltonSB, Winkelmayer WC, Hemmelgarn BR; Alberta Kidney Disease Network //Am JKidney Dis. – 2017.
- №69(6). – Р.734-743. doi: 10.1053/j.ajkd.2016.10.018.230. Jun M. The association between kidney function and major bleedingin older adults with atrial fibrillation starting warfarin treatment: population basedobservational study /Jun M, James MT, Manns BJ, Quinn RR, Ravani P, TonelliM, Perkovic V, Winkelmayer WC, Ma Z, Hemmelgarn BR //BMJ. – 2015. №350. – Р.h246.231. Jüttler E. Treatment and prevention of spontaneous intracerebralhemorrhage: comparison of EUSI and AHA/ASA recommendations /JüttlerE, Steiner T // Expert Rev Neurother. – 2007. - №7(10). - Р.
1401-1416.257232. Kakkar AK. International longitudinal registry of patients with atrialfibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD(GARFIELD) / Kakkar AK, Mueller I, Bassand JP, et al. // Am Heart J. – 2012. №163(1). – Р. 13-19.e1.233. Kakkar AK. Risk profiles and antithrombotic treatment of patientsnewly diagnosed with atrial fibrillation at risk of stroke: perspectives from theinternational, observational, prospective GARFIELD registry /Kakkar AK,Mueller I, Bassand JP, et al.
// PLOS One. - 2013. - №8. – Р.e63479.234. Kaplan NM. Clinical Hypertension /Kaplan NM // Philadelphia, PA:Lippincott, Williams & Wilkins, 2006.235. Karason K. Heart rate variability in obesity and the effect of weightloss /Karason K, Molgaard H, Wikstrand J, Sjostrom L // Am J Cardiol. – 1999. № 83. – Р.1242–1247.236. Katz DF. Contemporary Trends in Oral Anticoagulant Prescription inAtrial Fibrillation Patients at Low to Moderate Risk of Stroke After GuidelineRecommended Change in Use of the CHADS2to the CHA2DS2-VASc Score forThromboembolic Risk Assessment /Katz DF, Maddox TM, Turakhia M, Gehi A,O’Brien EC, Lubitz SA, Turchin A, Doros G, Lei L, Varosy P, Marzec L, Hsu JS// Circulation: Cardiovascular Quality and Outcomes. – 2017.
- №10. – Р.e003476237. Keskar V. The association of anticoagulation, ischemic stroke, andhemorrhage in elderly adults with chronic kidney disease and atrial fibrillation/Keskar V, McArthur E, Wald R, Harel Z, Zimmerman D, Molnar AO, Garg AX,Lam NN, McCallum MK, Bota SE, Perl J, Sood MM //Kidney Int. - 2017. №91(4). – Р.928-936.238. Kharlamov AN. Cardiovascular burden and percutaneous interventionsin Russian Federation: systematic epidemiological update /Kharlamov AN //Cardiovasc Diagn Ther.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
